May M, Fritsche H-M, Gilfrich C, Brookman-May S, Burger M, Otto W, Bolenz C, Trojan L, Herrmann E, Michel M S, Wülfing C, Tiemann A, Müller S C, Ellinger J, Buchner A, Stief C G, Tilki D, Wieland W F, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Müller O, Bretschneider-Ehrenberg P, Zacharias M, Gunia S, Bastian P J
Urologische Klinik, St. Elisabeth Klinikum Straubing, St. Elisabeth-Straße 23, 94315 Straubing, Deutschland.
Urologe A. 2011 Jul;50(7):821-9. doi: 10.1007/s00120-011-2507-9.
The therapeutic gold standard of muscle-invasive tumour stages is radical cystectomy (RC), but there are still conflicting reports about associated morbidity and mortality and the oncologic benefit of RC in elderly patients. The aim of the present study was the comparison of overall (OS) and cancer-specific survival (CSS) in patients <75 and >75 years of age (median follow-up was 42 months).
Clinical and histopathological data of 2,483 patients with urothelial carcinoma and consecutive RC were collated. The study group was dichotomized by the age of 75 years at RC. Statistical analyses comprising an assessment of postoperative mortality within 90 days, OS and CSS were assessed. Multivariate logistic regression and survival analyses were performed.
The 402 patients (16.2%) with an age of ≥75 years at RC showed a significantly higher local tumour stage (pT3/4 and/or pN+) (58 vs 51%; p=0.01), higher tumour grade (73 vs 65%; p=0.003) and higher rates of upstaging in the RC specimen (55 vs 48%; p=0.032). Elderly patients received significantly less often adjuvant chemotherapy (8 vs 15%; p<0.001). The 90-day mortality was significantly higher in patients ≥75 years (6.2 vs 3.7%; p=0.026). When adjusted for different variables (gender, tumour stage, adjuvant chemotherapy, time period of RC), only in male patients and locally advanced tumour stages was an association with 90-day mortality noticed. The multivariate analysis showed that patients ≥75 years of age have a significantly worse OS (HR=1.42; p<0.001) and CSS (HR=1.27; p=0.018).
An age of ≥75 years at RC is associated with a worse outcome. Prospective analyses including an assessment of the role of comorbidity and possibly age-dependent tumour biology are warranted.
肌层浸润性肿瘤分期的治疗金标准是根治性膀胱切除术(RC),但关于其相关发病率、死亡率以及RC对老年患者的肿瘤学获益仍存在相互矛盾的报道。本研究的目的是比较年龄<75岁和>75岁患者的总生存期(OS)和癌症特异性生存期(CSS)(中位随访时间为42个月)。
整理了2483例尿路上皮癌并接受连续性RC患者的临床和组织病理学数据。研究组根据RC时的年龄75岁进行二分法划分。进行了包括评估90天内术后死亡率、OS和CSS的统计分析。进行了多变量逻辑回归和生存分析。
RC时年龄≥75岁的402例患者(16.2%)显示局部肿瘤分期显著更高(pT3/4和/或pN+)(58%对51%;p=0.01),肿瘤分级更高(73%对65%;p=0.003),RC标本中分期上调率更高(55%对48%;p=0.032)。老年患者接受辅助化疗的频率显著更低(8%对15%;p<0.001)。≥75岁患者的90天死亡率显著更高(6.2%对3.7%;p=0.026)。在对不同变量(性别、肿瘤分期、辅助化疗、RC时间)进行校正后,仅在男性患者和局部晚期肿瘤分期中发现与90天死亡率有关联。多变量分析显示,年龄≥75岁的患者OS显著更差(HR=1.42;p<0.001),CSS也显著更差(HR=1.27;p=0.018)。
RC时年龄≥75岁与更差的预后相关。有必要进行前瞻性分析,包括评估合并症的作用以及可能的年龄依赖性肿瘤生物学特性。